References

Update on the epidemiology, risk factors, and disease outcomes of systemic sclerosis

10.1016/j.berh.2018.08.005 · 2018 · External reference

The role of B cells in the pathogenesis of systemic sclerosis: an update

10.1093/rheumatology/keac578 · 2023 · External reference

Current Concepts on the Pathogenesis of Systemic Sclerosis

10.1007/s12016-021-08889-8 · 2023 · External reference

Systemic sclerosis

10.1038/nrdp.2015.2 · 2015 · External reference

Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort

10.1186/s13075-021-02548-1 · 2021 · External reference

The immunopathogenesis of fibrosis in systemic sclerosis

10.1111/cei.13238 · 2019 · External reference

Pathogenetic Aspects of Systemic Sclerosis: A View Through the Prism of B Cells

10.3389/fimmu.2022.925741 · 2022 · External reference

Pathogenesis of Systemic Sclerosis

10.3389/fimmu.2015.00272 · 2015 · External reference

Involvement of B cells in the development of systemic sclerosis

10.3389/fimmu.2022.938785 · 2022 · External reference

Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial

10.1016/s2665-9913(21)00107-7 · 2021 · External reference

Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial

10.1016/s2213-2600(22)00359-9 · 2023 · External reference

Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis

10.1093/rheumatology/keaa550 · 2021 · External reference

Anti-CD20-mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives

10.1016/j.kint.2019.12.025 · 2020 · External reference

Non-response to rituximab therapy in rheumatoid arthritis is associated with incomplete disruption of the B cell receptor repertoire

10.1136/annrheumdis-2018-214898 · 2019 · External reference

CD19-CAR T-cell therapy induces deep tissue depletion of B cells

10.1136/ard-2024-226142 · 2025 · External reference

CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series

10.1016/s2665-9913(24)00282-0 · 2025 · External reference

CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up

10.1056/nejmoa2308917 · 2024 · External reference

Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-Myositis phase I/II trial

10.1016/j.ymthe.2024.09.009 · 2024 · External reference

Preclinical specificity & activity of a fully human 41BB-expressing anti-CD19 CART- therapy for treatment-resistant autoimmune disease

10.1016/j.omtm.2024.101267 · 2024 · External reference

Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis

10.5301/jsrd.5000231 · 2017 · External reference

The Stanford Health Assessment Questionnaire: dimensions and practical applications

10.1186/1477-7525-1-20 · 2003 · External reference

Single-factor scoring validation for the Health Assessment Questionnaire-Disability Index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients

10.1007/s11136-006-0018-8 · 2006 · External reference

New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis

10.1136/annrheumdis-2020-219100 · 2021 · External reference

Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells

10.1136/ard-2023-223952 · 2023 · External reference

6 months-follow up data of systemic sclerosis patients treated with CD 19 targeting CAR-T cells

2023 · External reference

Update of EULAR recommendations for the treatment of systemic sclerosis

10.1136/annrheumdis-2016-209909 · 2017 · External reference

Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies

10.1093/rheumatology/ker269 · 2012 · External reference

Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma

10.1056/nejmoa1703327 · 2018 · External reference

Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy

10.1016/j.omtm.2023.08.023 · 2023 · External reference

BAFF Produced by Neutrophils and Dendritic Cells Is Regulated Differently and Has Distinct Roles in Antibody Responses and Protective Immunity against West Nile Virus

10.4049/jimmunol.1901120 · 2020 · External reference

B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial

10.1136/annrheumdis-2021-220920 · 2022 · External reference

Coding joint: kappa-deleting recombination excision circle ratio and B cell activating factor level: predicting juvenile dermatomyositis rituximab response, a proof-of-concept study

10.1186/s41927-022-00265-z · 2022 · External reference

Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production

10.1136/ard.2006.060772 · 2007 · External reference

B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial

10.1186/ar2965 · 2010 · External reference

Challenges and Opportunities for Consistent Classification of Human B Cell and Plasma Cell Populations

10.3389/fimmu.2019.02458 · 2019 · External reference

Transitional B cells in humans: characterization and insight from B lymphocyte reconstitution after hematopoietic stem cell transplantation

10.1016/j.clim.2007.11.013 · 2008 · External reference

First evidence for efficacy of CAR T cell treatment in refractory antisynthetase syndrome [abstract]

10.1136/annrheumdis-2023-eular.3842 · 2023 · External reference

A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, In SYstemic sclerosis: DAISY study design and rationale

2024 · External reference

Analysis of IL-6 serum levels and CAR T cell-specific digital PCR in the context of cytokine release syndrome

10.1016/j.exphem.2020.07.003 · 2020 · External reference

Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus

10.1038/s41591-022-02017-5 · 2022 · External reference

Patient and Physician Global Assessments of Disease Status in Systemic Sclerosis

10.1002/acr.25056 · 2023 · External reference

Prevalence, severity, and clinical correlates of pain in patients with systemic sclerosis

10.1002/acr.20108 · 2010 · External reference

Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system

10.1016/s0885-3924(96)00274-6 · 1997 · External reference

[Nailfold capillaroscopy-Principles and clinical application]

2022 · External reference

Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis

10.1016/j.autrev.2020.102458 · 2020 · External reference

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

10.1126/scitranslmed.3002842 · 2011 · External reference

Determining lower limits of detection of digital PCR assays for cancer-related gene mutations

10.1016/j.bdq.2014.08.001 · 2014 · External reference

Insights on Droplet Digital PCR-Based Cellular Kinetics and Biodistribution Assay Support for CAR-T Cell Therapy

10.1208/s12248-021-00560-6 · 2021 · External reference